Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Practical considerations in first-line treatment of mCRPC

Noel Clarke

8 Practical considerations in first-line treatment of mCRPC - Noel Clarke

Professor Noel W Clarke, Salford Royal Hospital and The Christie, Manchester presents the case of a 58 year old man with asymptomatic adenocarcinoma of the prostate (cT3 Gleason) and metastases initially treated with androgen ablation as monotherapy. After a first decline of prostate-specific antigen (PSA), PSA levels rise and a progressive metastatic castrate resistant prostate cancer developed. The question is how to treat this patient: continuing androgen deprivation therapy (ADT), ADT plus bicalutamide, novel androgen targeting agents or docetaxel?